Designation of Mifamurtide (Mepact) as an Orphan Drug - Nycomed Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was established to regulate therapeutic goods, including medicines, medical devices, and blood and blood components, with the aim of ensuring their safety, quality, and efficacy. The Act provides a legislative framework for the control of therapeutic goods and was introduced to address the need for a cohesive and comprehensive regulatory system that safeguards public health. The Therapeutic Goods Administration (TGA), under the Department of Health and Ageing, administers the Act and its associated regulations, such as the Therapeutic Goods Regulations 1990, which were amended to include provisions for designating orphan drugs. In the case of Mifamurtide (Mepact), the TGA designated it as an orphan drug to address the gap in treatment options for rare diseases like osteosarcoma, reflecting the policy objective of supporting the development of therapeutics for conditions that affect a small patient population and therefore have limited commercial incentives for pharmaceutical companies.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) within the Department of Health and Ageing, governs the regulation of therapeutic goods in Australia. This Act applies to a broad range of therapeutic goods, including medicines, medical devices, blood and blood components, tissues, and therapeutic goods containing radionuclides. The Act's jurisdictional reach is national, as it applies throughout the Commonwealth of Australia, ensuring a uniform standard for therapeutic goods across the country. The Act applies to entities and individuals involved in the importation, manufacture, supply, and advertising of therapeutic goods. Notably, the Act includes specific provisions for the designation of orphan drugs, which are intended for the treatment of rare medical conditions. Mifamurtide (Mepact), designated as an orphan drug under this Act, is specifically designated for the treatment of osteosarcoma. The application of the Act may be extended or restricted through subordinate instruments such as regulations and guidelines, ensuring the Act remains responsive to evolving therapeutic needs and regulatory requirements.

Key Provisions

The Therapeutic Goods Act 1989, under the authority of the Therapeutic Goods Regulations 1990, designates Mifamurtide (Mepact) as an orphan drug effective from 2 September 2013. This designation (Regulations 16J(2)) is for the treatment of osteosarcoma, a type of bone cancer, and specifies that the drug will be in the form of powder for infusion. The sponsor of Mifamurtide (Mepact) is Nycomed Pty Ltd. This legislative action recognises the rarity of osteosarcoma and aims to encourage the development of treatments for conditions that affect a small number of people. The obligations imposed by this designation on the parties involved, particularly Nycomed Pty Ltd as the sponsor, include ensuring that Mifamurtide (Mepact) meets the necessary standards for safety, quality, and efficacy as stipulated by the Therapeutic Goods Administration. The sponsor must also provide comprehensive data and documentation to support the orphan drug designation, including clinical trial results and other relevant information. This process ensures that the drug is both safe and effective for its intended use and that it will be available for patients who need it. Failure to comply with the requirements set out in the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in significant consequences. Offences under this legislation can lead to both civil and criminal penalties. For instance, the Act provides for the imposition of fines up to $2,200,000 for corporations and $440,000 for individuals for breaches of the Act (Section 31). In more severe cases, imprisonment may also be imposed, with penalties reaching up to five years for individuals and ten years for corporations (Section 32). These stringent measures underscore the importance of adherence to the regulatory framework governing therapeutic goods in Australia.